Free Trial

Aldeyra Therapeutics (ALDX) Competitors

Aldeyra Therapeutics logo
$5.50 +0.06 (+1.01%)
As of 12:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ALDX vs. XERS, NUVB, AMLX, IMTX, ELVN, TRML, TRVI, IMNM, WVE, and CVAC

Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Xeris Biopharma (XERS), Nuvation Bio (NUVB), Amylyx Pharmaceuticals (AMLX), Immatics (IMTX), Enliven Therapeutics (ELVN), Tourmaline Bio (TRML), Trevi Therapeutics (TRVI), Immunome (IMNM), WAVE Life Sciences (WVE), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.

Aldeyra Therapeutics vs. Its Competitors

Xeris Biopharma (NASDAQ:XERS) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Xeris Biopharma presently has a consensus target price of $7.08, suggesting a potential downside of 22.71%. Aldeyra Therapeutics has a consensus target price of $9.50, suggesting a potential upside of 72.88%. Given Aldeyra Therapeutics' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Xeris Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
Aldeyra Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Xeris Biopharma has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Xeris Biopharma has higher revenue and earnings than Aldeyra Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Biopharma$203.07M7.29-$54.84M-$0.21-43.64
Aldeyra TherapeuticsN/AN/A-$55.85M-$0.85-6.46

Aldeyra Therapeutics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -13.01%. Xeris Biopharma's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xeris Biopharma-13.01% N/A -8.00%
Aldeyra Therapeutics N/A -73.63%-50.61%

In the previous week, Xeris Biopharma had 6 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 6 mentions for Xeris Biopharma and 0 mentions for Aldeyra Therapeutics. Xeris Biopharma's average media sentiment score of 0.81 beat Aldeyra Therapeutics' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Xeris Biopharma Positive
Aldeyra Therapeutics Neutral

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Xeris Biopharma beats Aldeyra Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Aldeyra Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALDX vs. The Competition

MetricAldeyra TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$328.53M$2.65B$6.16B$10.63B
Dividend YieldN/A57.79%5.72%4.85%
P/E Ratio-6.4524.1129.4927.39
Price / SalesN/A589.35494.36189.83
Price / CashN/A27.2425.8230.35
Price / Book4.625.4212.466.70
Net Income-$55.85M$33.06M$3.32B$276.34M
7 Day Performance2.90%2.79%2.21%0.29%
1 Month Performance11.46%12.09%9.00%4.13%
1 Year Performance-0.63%-0.96%63.72%33.94%

Aldeyra Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALDX
Aldeyra Therapeutics
2.0666 of 5 stars
$5.50
+1.0%
$9.50
+72.9%
-4.6%$328.53MN/A-6.4510
XERS
Xeris Biopharma
3.1715 of 5 stars
$7.95
-0.5%
$7.08
-10.9%
+205.2%$1.29B$203.07M-37.86290News Coverage
Analyst Upgrade
NUVB
Nuvation Bio
2.4233 of 5 stars
$3.69
-1.5%
$7.86
+113.2%
+48.4%$1.28B$7.87M-5.8560
AMLX
Amylyx Pharmaceuticals
2.3227 of 5 stars
$14.12
-1.0%
$14.75
+4.5%
+221.5%$1.27B$87.37M-5.65200Gap Up
IMTX
Immatics
2.9283 of 5 stars
$10.09
-2.6%
$13.67
+35.4%
+10.9%$1.26B$168.65M-15.52260News Coverage
ELVN
Enliven Therapeutics
1.9482 of 5 stars
$20.68
-0.7%
$41.20
+99.2%
-23.7%$1.23BN/A-10.3450
TRML
Tourmaline Bio
1.6233 of 5 stars
$47.91
+0.1%
$45.65
-4.7%
+69.6%$1.23BN/A-13.9744Positive News
Short Interest ↓
TRVI
Trevi Therapeutics
2.6816 of 5 stars
$9.71
-2.8%
$21.75
+124.0%
+242.6%$1.22BN/A-23.1220Gap Down
IMNM
Immunome
1.6385 of 5 stars
$14.25
+2.4%
$23.20
+62.8%
+32.3%$1.21B$9.04M-4.6340
WVE
WAVE Life Sciences
4.7377 of 5 stars
$7.79
+2.5%
$20.33
+161.0%
-49.0%$1.21B$108.30M-8.66240Analyst Forecast
CVAC
CureVac
3.5231 of 5 stars
$5.39
+0.2%
$6.83
+26.8%
+91.4%$1.21B$579.18M5.61880

Related Companies and Tools


This page (NASDAQ:ALDX) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners